Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 647.19

+0.5%

Nov 6 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (308)	6/18/1999 8:56:00 AM
From: Dr. John M. de Castro	Read Replies (2) of 3557

REGN Science paper. These are potentially very important findings that have implications for treatment and diagnostic testing for cancer. biz.yahoo.com The following is the exerpt from the Science Online synopsis of the article. "Solid tumors need a blood supply in order to grow. Conventional models suggest that most tumors initially grow as avascular masses that induce growth of new blood vessels once they reach about 1 millimeter in size. Holash et al. (p. 1994) show that, at least for some tumors, early events in tumor angiogenesis may be more complex. Experimentally induced tumors in rodents (C6 gliomas) initially grew by "coopting" preexisting blood vessels from the surrounding tissue. Surprisingly, these coopted vessels then regressed (which resulted in transient tumor regression, only to be replaced by newly made vessels that facilitated tumor growth. The expression patterns of anti-angiogenic angiopoietin-2 and pro-angiogenic vascular endothelial growth factor suggest that these proteins are involved in a critical balancing act that helps determine whether a tumor successfully establishes itself in the host." John de C

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next